The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2023 | A novel composite endpoint of toxicity and PFS in patients with R/R FL treated with axi-cel
Razan Mohty, MD, Moffitt Cancer Center, Tampa, FL, summarizes the key points of a study evaluating a novel composite endpoint of toxicity and progression-free survival (PFS) in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with axicabtagene autoleucel (axi-cel). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
